BRAINSTORM CELL THERAPEUTICS INC.
BCLI evidence brief
What we can confirm
- BioSniper Score:
- 1.5 / 10
- Market Cap:
- $11.9M
- Cash Runway:
- 0.1 mo
What it means
What to watch
Prepared research question
What matters most for BCLI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCLI
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company developing NurOwn®, an autologous cell therapy platform for neurodegenerative diseases, currently focused on a Phase 3b trial for ALS after FDA alignment on a Special Protocol Assessment.
Key risk: Zero cash position
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for BRAINSTORM CELL THERAPEUTICS INC..
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company developing NurOwn®, an autologous cell therapy platform for neurodegenerative diseases, currently focused on a Phase 3b trial for ALS after FDA alignment on a Special Protocol Assessment.
- Cash & equivalents were $0.0M as of 2026-06-30 [sec].
- Net income was -$3.9M as of 2026-06-30 [sec].
- Shareholders' equity was -$11.6M as of 2026-06-30 [sec].
- The company secured $2.0 million in strategic financing in early 2026 [news · published 2026-03-31].
- FDA granted a Special Protocol Assessment (SPA) agreement for the Phase 3b trial of NurOwn® in ALS in April 2024 [sec_mda · as of 2026-08-14].
What works
- NurOwn® is an autologous cell therapy platform that avoids alloimmunity, rejection risk, and the need for immunosuppressive agents [sec_mda · as of 2026-08-14].
- The company has secured FDA alignment on both a Special Protocol Assessment (SPA) and Chemistry, Manufacturing, and Controls (CMC) for its planned Phase 3b ALS trial [sec_mda · as of 2026-08-14].
- The company highlights durable long-term survival data from its Expanded Access Program (EAP) cohort, supporting Phase 3b patient selection and inclusion criteria [news · published 2026-03-31].
What to weigh
- Cash & equivalents were $0.0M as of 2026-06-30, indicating a critical liquidity position [sec].
- Shareholders' equity was -$11.6M as of 2026-06-30, reflecting negative net worth [sec].
- The company expects continued losses and negative cash flow from operating activities, and substantial additional capital is needed to conduct the Phase 3b trial and commercialize NurOwn® [sec_mda · as of 2026-08-14].
- If the company cannot raise additional capital, it may not be able to continue as a going concern [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
FDA SPA agreement for Phase 3b trial
“the Company announced that it received written agreement from the FDA, under a SPA, on the design for a Phase 3b trial of NurOwn® in ALS”
SEC MD&A · August 14, 2026
Going concern risk if capital not raised
“If the Company is not able to raise additional capital for these purposes, the Company may not be able to continue to function as a going concern.”
SEC MD&A · August 14, 2026
Strategic financing of $2.0 million in early 2026
“the $2.0 million in strategic financing secured in early 2026”
News · March 31, 2026
Risks & what to watch (4)›
Key risks
- Zero cash position — Cash & equivalents were $0.0M as of 2026-06-30, indicating immediate liquidity risk [sec].
- Negative shareholders' equity — Shareholders' equity was -$11.6M as of 2026-06-30, reflecting negative net worth [sec].
- Going concern risk — If additional capital is not raised, the company may not continue as a going concern [sec_mda · as of 2026-08-14].
- Continued operating losses — The company expects continued losses and negative cash flow from clinical development and regulatory activities [sec_mda · as of 2026-08-14].
What to watch
- Ability to raise additional capital to fund the Phase 3b ENDURANCE study and ongoing operations [sec_mda · as of 2026-08-14].
- Execution of the Phase 3b ENDURANCE study of NurOwn for ALS, expected to enroll approximately 200 participants [news · published 2026-03-31].
- Regulatory progress and any updates from FDA interactions regarding the BLA path for NurOwn [sec_mda · as of 2026-08-14].
- Financial results and cash runway updates in future SEC filings, given the zero cash position as of mid-2026 [sec].
Sources: News · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run BRAINSTORM CELL THERAPEUTICS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BRAINSTORM CELL THERAPEUTICS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
0.1 months
OCF -$895K · Net income -$4M
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2025Institutional holders
5
Total value held
$2K
| Holder | Shares | Value |
|---|---|---|
| osaic holdings, inc. | 1,785 | $1K |
| bangor savings bank | 266 | $188 |
| vsm wealth advisory, llc | 120 | $85 |
| steward partners investment advisory, llc | 113 | $80 |
| st germain d j co inc | 33 | $23 |
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 1.3
- Shares short
- 604,460
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCLI short interestGovernance
Frequently asked questions
What is the AI investment thesis for BRAINSTORM CELL THERAPEUTICS INC.?
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company developing NurOwn®, an autologous cell therapy platform for neurodegenerative diseases, currently focused on a Phase 3b trial for ALS after FDA alignment on a Special Protocol Assessment.
What is BRAINSTORM CELL THERAPEUTICS INC.'s lead drug candidate?
BRAINSTORM CELL THERAPEUTICS INC.'s most advanced tracked candidate is nurown (Preclinical) for Alzheimer's disease (AD).
Who is the CEO of BRAINSTORM CELL THERAPEUTICS INC.?
Mr. Chaim Lebovits is the chief executive officer of BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
Where is BRAINSTORM CELL THERAPEUTICS INC. headquartered?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is headquartered in New York, NY, United States.
What therapeutic areas does BRAINSTORM CELL THERAPEUTICS INC. focus on?
BRAINSTORM CELL THERAPEUTICS INC. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.